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interviews with 14 key informants including patients and their
spouses. Interview responses were recorded, transcribed and
organized thematically based on emerging codes using an induc-
tive analysis. Discussion with attending physicians, nurses, and
pharmacists at the clinic was also incorporated as data triangu-
lation. RESULTS: Potential problems in the patient-provider
communication included unfriendly welcoming or disgusted
reactions; disclosure of conﬁdential matters; and health care
environment factors. Compared with their previous experiences
at other health care facilities, the patients were very satisﬁed with
genuine and empathetic providers at this site. Moreover, they
perceived that the providers were more highly trained specialists
with effective communication skills, which encouraged the
patients to ask questions regarding their health. In addition, a
hotline number was provided so the patients could contact the
clinic whenever they encountered any health-related problems or
needed assistance. Thus, a trusted therapeutic rapport was estab-
lished with a positive impact on the patient-physician’s commit-
ment to care which resulted a good adherence. CONCLUSIONS:
Provider-patient communication contributes to patient satisfac-
tion with medical treatment which is extremely important in
HIV/AIDS care. As numerous issues facilitate or inhibit construc-
tive relationships between providers and patients, it is essential
for doctors to be aware of their power when dealing with
patients, particularly in this consumer empowerment era. Good
communication is essential to good practice of medicine and its
rewards are immeasurable for both patients and providers.
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OBJECTIVES: To assess the health-related quality of life
(HRQoL) among patients with venous leg ulcer (VLU) in the US
and UK. METHODS: A prospective, observational, multi-center
study was conducted among 112 patients with VLU in the US
(76 patients) and the UK (36 patients) between 2007 and 2008.
Patients completed a generic health status measure, the EuroQol
(EQ-5D) Questionnaire1 and a disease-speciﬁc health-related
quality of life measure, the Charing Cross Leg Ulcer Question-
naire2 at study baseline and at the end of the study. Patients
were provided routine medical care for their ulcer for a study
period of 12 weeks or until all their ulcers healed. Analyses
were conducted to assess the change in HRQoL scores over the
study period among all patients, among patients with all ulcers
healed (healed patients) and among patients with at least one
ulcer not healed (non-healed patients). RESULTS: The mean age
(SD) of VLU patients was 61.9 (13.7) years in the US and was
70.9 (13.9) years in the UK. A total of 51.3% of VLU patients
in the US were males while 36.1% in the UK were males. At
baseline, the mean (SD) EQ-5D index score was 0.6628
(0.2402) for US patients and 0.6206 (0.3413) for UK patients.
There was a statistically signiﬁcant improvement in EQ-5D
index scores over the study period among the US healed patients
(p < 0.01) but not for US non-healed patients or UK patients.
Among all patients, the Charing Cross Leg Ulcer Questionnaire
showed that patients’ social interaction (p < 0.01) and emo-
tional status (p < 0.01) were signiﬁcantly improved during the
study period. CONCLUSIONS: VLU results in a signiﬁcant
negative impact on patients’ health status. Treatments for VLU
that promote ulcer healing are likely to result in signiﬁcant
improvements in patients’ health-related quality of life. EU-08–
1532. © 2008 ER. Squibb & Sons, LL.C. 1 The EuroQuol
Group. www.euroqol.org; accessed 01/02/2007 2 Smith J, et al.
Measuring the quality of life in patients with venous leg ulcers.
J Vasc Surg 2000;31:642–9.
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OBJECTIVES: To document the psychometric properties and
estimate a minimal important difference (MID) for the Sinonasal
Outcome Test-16 (SNOT-16) in patients with acute bacterial
sinusitis. METHODS: Secondary psychometric analysis was
undertaken on data from a phase III trial to evaluate the efﬁcacy
and safety of moxiﬂoxacin over 5 consecutive days in the treat-
ment of acute bacterial sinusitis (N = 374). Trial patients also
completed the RAND SF-36, the Activity Impairment Assess-
ment (AIA) and a global rating of change. The SNOT-16 has 16
items and is scored as a uni-dimensional measure of symptoms
of rhinosinusitis. Internal consistency and construct validity
(against SF-36 and AIA) were assessed at baseline. Sensitivity and
MID were assessed by comparing test of cure data against base-
line using statistical methods (effect size (ES), standardised
response mean (SRM); and standard error of measurement
(SEM) and 1/2 standard deviation (1/2SD)) and anchor methods
against the smallest change on the global rating of change.
Missing data were imputed using last observation carried
forward. RESULTS: Internal consistency (a = 0.874) and con-
struct validity (SF-36 Role Function r = -0.44; Vitality r = 0.45,
Social Function r = 0.48, Pain r = 0.51, AIA r = 0.67 all P <
0.001) were conﬁrmed. The SNOT-16 was sensitive (ES = 1.68;
SRM = 1.36). The MID estimated by the anchor method was
-0.85; but MID was lower by distributional estimates
(SEM = 0.21, 1/2SD = 0.29). CONCLUSIONS: The study con-
ﬁrms the good psychometric properties of the SNOT-16 in
patients with acute bacterial sinusitis and demonstrates the sen-
sitivity and MID for this measure. The 3 MID estimates were
widely separated and the higher anchor based estimate was
settled on.
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OBJECTIVES: To document the psychometric properties and
estimate a minimal important difference (MID) for the Activity
Impairment Assessment (AIA) questionnaire in patients with
acute bacterial sinusitis. The AIA has previously been validated
in people with uncomplicated urinary tract infections.
METHODS: Secondary psychometric analysis was undertaken
on data from a phase III trial to evaluate the efﬁcacy and safety
of moxiﬂoxacin over 5 consecutive days in the treatment of acute
bacterial sinusitis (N = 374). Trial patients also completed the
RAND SF-36, the Sinonasal Outcomes Test-16 (SNOT-16) and a
global rating of change. The AIA has 5 items and is scored as a
uni-dimensional measure of the impact of disease on an individu-
al’s work or regular activities. Internal consistency and construct
validity (against SF-36 and SNOT-16) were assessed at baseline.
Sensitivity and MID were assessed by comparing test of cure data
against baseline using statistical methods (effect size (ES), stan-
dardised response mean (SRM); and standard error of measure-
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ment (SEM) and 1/2 standard deviation (1/2SD)) and anchor
methods against the smallest change on the global rating of
change. Missing data were imputed using last observation carried
forward. RESULTS: Internal consistency (a = 0.940) and con-
struct validity (SF-36 Role Function r = -0.66; Vitality r = 0.62,
Social Function r = 0.71, Pain r = 0.64, SNOT-16 r = 0.67 all
P < 0.001) were conﬁrmed with strong correlations. The AIA
was sensitive (ES = 0.90; SRM = 0.82). The MID estimated by
the anchor method was 2.63; but MID was lower by distribu-
tional estimates (SEM = 1.39, 1/2SD = 2.84). CONCLUSIONS:
The study conﬁrms the good psychometric properties of the AIA
in patients with acute bacterial sinusitis and demonstrates the
sensitivity and MID for this measure. Distributional MID esti-
mates conﬁrmed the anchor based approach.
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OBJECTIVES: Most Heath-Related Quality of Life (HRQL)
questionnaires speciﬁc to HIV/AIDS were developed when HIV
was a deadly disease. They do not adequately measure the
impact of the disease and its treatment on People Living With
HIV/AIDS (PLWA) anymore. Relevant domains are missing
such as perception about treatment, impact of side effects, lipo-
dystrophy and sleep. Psycho-social impact, especially stigma, is
under-evaluated. The objective is to develop a new Patient-
Reported Outcomes (PRO) questionnaire to measure the
HRQL of PLWA in different countries using an item bank
developed with patients. METHODS: The conceptual frame-
work was identiﬁed on the basis of patients’ interviews. To
capture the cultural differences in patients’ perceptions, the
interviews were held in the ﬁve continents: Africa (Senegal),
America (Brazil, USA), Australia, Asia (Thailand, China, Cam-
bodia, India) and Europe (France). All interviews were
recorded, transcribed and translated into English or French.
Important verbatim were selected, transformed into items and
organized into a questionnaire developed in French and in
English. ). All interviews were recorded, transcribed and trans-
lated into English or French. Important verbatim were selected,
transformed into items and organized into a questionnaire
developed in French and in English. RESULTS: A total of 148
patients were interviewed (47% women), and PRO concepts
important to the patients were identiﬁed. An endpoint model
was designed to explain the relations between PROs: health
status, symptoms, side effects and HRQL domains. Cultural
differences were identiﬁed in daily activities, stigma and rela-
tions with family and friends. 300 items were generated in
French and in English and organized into a 24-domain item
bank. Item reduction to a 70-item questionnaire was done with
experts. Full linguistic validation process was performed. CON-
CLUSIONS: A new PRO questionnaire speciﬁc to HIV was
developed. The international development from an early step
will enable a better cultural relevance and has improved the
translatability of the source questionnaires (French and English)
into the target languages. The international psychometric vali-
dation study with 900 patients is ongoing.
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OBJECTIVES: To develop an understanding of the adoption
decision process for vaccines, and the role of value demonstration
(cost-effectiveness) in that process. METHODS: The literature
was searched for a) general information on decision criteria
applicable to vaccines; b) information speciﬁc to vaccine value
demonstration; and c) cost-effectiveness analyses for HPV, pneu-
mococcal disease, and dTpa as examples of vaccines recently
adopted. Informationwas extracted by two reviewers to outline a)
the general factors affecting vaccine adoption, and b) the role of
value demonstration, and (c) what inﬂuences vaccine value dem-
onstration. RESULTS: Four published guidelines were identiﬁed
which outline factors to consider in the vaccine adoption process.
Thesewere combined to produce the following framework: 1) The
disease: is it a high priority, and an important public health
issue? 2) The vaccine: is it safe and effective in reducing disease
incidence? 3) The value: is it cost-effective? 4) The socio-political
climate: what are the concerns of the major stakeholders and how
can they be addressed? and 5) The feasibility: are there sufﬁcient
resources to adopt the vaccine? Factors identiﬁed as important in
determining vaccine cost-effectivenesswere: Vaccine efﬁcacy—the
more effective, including herd immunity effects, the higher the
perceived value; Disease incidence—the higher the incidence,
the greater the potential beneﬁt and therefore value; Disease
sequalae—the more severe and frequent the sequalae, the higher
the potential value in avoiding the condition; and Duration of
immunity—the longer the duration, the higher the value as fewer
boosters are required. CONCLUSIONS: While we were able to
synthesise a framework to describe the vaccine adoption process,
no information was found in the literature on how the elements of
that framework might be combined, ranked or weighted to reach
a decision. Further research into the relative weighting of these
factors is warranted.
PIN51
EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT
A LARGE INNER-CITY ACADEMIC MEDICAL CENTER INTHE
SURVIVING SEPSIS CAMPAIGN ERA
Ohuabunwo CJ1, Fotzeu C1, Heisler M2,VanDenBerg C3
1Morehouse School of Medicine, Atlanta, GA, USA, 2Emory
UNiversity, Atlanta, GA, USA, 3Grady Health System, Atlanta, GA,
USA
OBJECTIVES:Assess the severe sepsis diagnosis andmanagement
practices based on the SSC guidelines and quality indicators.
Determine the case severity level and outcomes of severe sepsis in
an inner city hospital setting. Ascertain the average direct cost of
severe sepsis hospitalization in this setting. METHODS: Using an
explanatory cross-sectional evaluation design, demographic,
administrative, clinical and laboratory data of all patients with
physician- diagnosed sepsis admitted during March–May 2007
were reviewed. The SSC-IHI severe sepsis screening/chart mea-
surement tools and quality indicatorswere used for data collection
and performance assessment respectively. Process measures were;
time-to-blood culture, blood culture-antibiotic sequence, time-to-
antibiotic, CVP goal, CV Oxygen saturation goal, Low-dose
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